Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Optometrists are seeing recent advances in topical therapies that entered the market following decades of reliance of traditional single-agent drops. An implantable device that facilitates the slow release of drug is changing the landscape in glaucoma therapy.

Justin Schweitzer, OD, FAAO, reports that glaucoma therapy is quickly moving to more innovative and targeted ways to treat glaucoma and lower the patient treatment burden.

With the launch of dark adaptation, Heru is now the only platform on the AMD market to include contrast sensitivity and dark adaptation exams.

Those who use oral contraceptives have improved dry eye symptoms, according to research.

Low prediction errors from 2 evaluated formulas shows promise for accurate prediction of IOL formulas in high myopic patients.

Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.

After a brief hiatus during the pandemic, Orbis' Flying Eye Hospital program returns.

Clinical pilot study evaluates effect after 1 month of wear.

OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone that has the potential to be the first topical eye drop and non-invasive treatment for DME.

The jury is still out on whether wearing glasses is associated with a decreased risk of COVID-19 infections.

Bausch + Lomb and Novaliqu announced that the FDA has accepted its New Drug Application for NOV03, an investigational treatment for dry eye disease associated with meibomian gland dysfunction.

These new testing kits permit more equitable access to coronavirus testing.

Postoperative scenario tracks potential complications.

Japanese researchers conducted a systematic review that identified clinical features and host factors associated with corneal allograft rejection after COVID-19 vaccination.

A recent study shows US adults with hearing and visual impairments have lower rates of vaccination for the coronavirus.

Jamie Ho, OD, FAAO, FCOVD, shares highlights from her SCOPA 2022 presentation, "Tools and considerations for low vision rehabilitation."

Jamie Ho, OD, FAAO, FCOVD, shares highlights from her SCOPA 2022 presentation, "Concussion for the primary care optometrist."

Brad Sutton, OD, FAAO, FORS, shares highlights from his SCOPA 2022 presentation, "Taking the mystery out of abnormal pupils."

Brad Sutton, OD, FAAO, FORS, shares highlights from his SCOPA 2022 presentation, "Anterior segment laser procedures."